HJ Science Co., Ltd.
6132.HK
Hong Kong Stock Exchange32.14
HKD
-1.86
- -
ISIN
CNE100007PD2
Return %
Stock
S&P500
1Y
-8.85
20.47
3Y
-8.85
70.50
5Y
-8.85
72.10
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jian Xin Ji
- Full Time Employees
- 115
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- No. 18 N. Sec of Bayi Rd Yongning Town Chengdu SI People's Republic of China 610000
- IPO Date
- Jun 23, 2026
- Website
- hj3h.com
- Similar Companies
- Business
- HJ Science Co., Ltd. engages in the research, development, and commercialization of innovative small-molecule drugs in the biotechnology and pharmaceutical sector, focusing on metabolic diseases, oncology, and autoimmune disorders. The company develops a diversified pipeline including HJ787, a selective TYK2 inhibitor for atopic dermatitis and acne vulgaris; HJ178, an oral agent for type 2 diabetes; and HJ891, an oral KRAS inhibitor with intravenous formulation for non-small-cell lung cancer; plus HJ197 in clinical-stage development for hepatocellular carcinoma and five preclinical candidates—HJ356, HJ093, HJ199, HJ198, and HJ086 addressing cardiovascular disease, atherosclerosis, and solid tumors. HJ Science operates primarily in China, with activities extending to international partnerships and potential collaborations to advance clinical programs, manufacturing, and commercialization. The company was founded in 2017 and is headquartered in Chengdu, Sichuan Province, China, and is listed on the Hong Kong Stock Exchange under ticker 6132.HK. Its business model encompasses discovery research, preclinical testing, clinical development, and strategic partnerships to translate novel mechanisms into therapeutic candidates across multiple indications. Subsidiaries and affiliates support integrated R&D, regulatory affairs, and manufacturing scaling as part of a broader corporate strategy to establish a multi-program pipeline with potential global reach. Recent corporate developments include enhanced collaboration with strategic partners to accelerate clinical programs, exploration of funding opportunities to support ongoing trials, and continuation of targeted expansions in drug discovery and preclinical optimization to broaden the portfolio and potential market access. These elements position HJ Science as a rising biotech entity pursuing a diversified approach to novel therapeutics within its core segments while pursuing internationalization and potential US/EU partner engagement.